OriCAR-017
Phase 2Biologic
OriCAR-017 is one of 43 biologic programs targeting PK/PD. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
350 competitors in Treatment
#DrugCompanyPhaseTrials
1Alfenta
Jazz PharmaceuticalsPreclinical
Niclocide
BayerPreclinical
Theo-Dur
PfizerPreclinical
Levulan
Sun Pharmaceutical Industries, Inc.Preclinical
Lamprene
NovartisPreclinical
Emtriva
GileadPreclinical
Hivid
CConrado Roberto Hoffmann Filho
Preclinical
Foscavir
CClinigen, Inc.
Preclinical
OriCAR-017
OOriCell Therapeutics Co., Ltd.
Phase 2
Clomid
FerringPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for OriCAR-017. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- OOriCell Therapeutics Co., Ltd.